Therapeutic potential for protein kinase C inhibitor in vascular restenosis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 16, Issue 2, 2011, Pages 160-167

  Ding, Richard Qinxue ^a   Tsao, Jerry ^b   Chai, Hong ^a   Mochly Rosen, Daria ^c   Zhou, Wei ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Migration; Proliferation; Protein kinase C; Smooth muscle cell; Vascular restenosis

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2,4 DIAMINO 5 NITROPYRIMIDINE DERIVATIVE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; 4,5 BIS(4 FLUOROANILINO)PHTHALIMIDE; 5 VINYL 3 PYRIDINECARBONITRILE DERIVATIVE; 7 HYDROXYSTAUROSPORINE; APRINOCARSEN; BALANOL; CALPHOSTIN C; CHELERYTHRINE; ENZASTAURIN; ISIS 9606; KAI 1678; KAI 9803; KCE 12; KCE 16; LY 379196; MIDOSTAURIN; PACLITAXEL; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; ROTTLERIN; RUBOXISTAURIN; SOTRASTAURIN; SPHECIOSTEROL SULFATE C; STAUROSPORINE; TAMOXIFEN; UNCLASSIFIED DRUG;

CELL MIGRATION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; LEUKOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOCYTE ACTIVATION; VASCULAR RESTENOSIS;

ANIMALS; CELL PROLIFERATION; HUMANS; INFLAMMATION; ISOENZYMES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; THROMBOSIS; VASCULAR DISEASES;

EID: 79960179082     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410382106     Document Type: Review

References (90)

1. Heckenkamp J, Gawenda M, Bnmkwall J. Vascular restenosis. Basic science and clinical implications. J Cardiovasc Surg (Torino). 2002;43(3):349-357. (Pubitemid 34752531)
2. Schiele TM, Krotz F, Klauss V. Vascular re stenosis-striving for therapy. Expert Opin Pharmacother. 2004;5(11):2221-32.
3. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol. 2006;59(3):232-239. (Pubitemid 43344881)
4. Kraitzer A, Kloog Y, Zilberman M. Approaches for prevention of restenosis. J Biomed Mater Res B Appl Biomater. 2008;85(2): 583-603. (Pubitemid 351600466)
5. Zargham R. Preventing restenosis after angioplasty: a multistage approach. Clin Sci (Lond). 2008;114(4):257-264. (Pubitemid 351294001)
6. Meier M, King GL. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vase Med. 2000;5(3):173-185.
7. Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D. PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu Rev Pharmacol Toxicol. 2008;48:569-599. (Pubitemid 351738164)
8. Grange JJ, Baca-Regen LM, Nollendorfs AJ, Persidsky Y, Sudan DL, Baxter BT. Protein kinase C isoforms in human aortic smooth muscle cells. J Vase Surg. 1998;27(5):919-926.
9. Mattila P, Majuri ML, Tiisala S, Renkonen R. Expression of six protein kinase C isotypes in endothelial cells. Life Sci. 1994; 55(16):1253-1260. (Pubitemid 24290434)
10. Magid R, Davies PF. Endothelial protein kinase C isoform identity and differential activity of PKCzeta in an athero-susceptible region of porcine aorta. Circ Res. 2005;97(5):443-449. (Pubitemid 41298174)
11. Duan C. The chemotactic and mitogenic responses of vascular smooth muscle cells to insulin-like growth factor-I require the activation of ERK1/2. Mol Cell Endocrinol. 2003;206(1-2):75-83. (Pubitemid 37011253)
12. Yamaguchi H, Igarashi M, Hirata A, et al. Altered PDGF-BBinduced p38 MAP kinase activation in diabetic vascular smooth muscle cells: roles of protein kinase C-delta. Arterioscler Thromb Vase Biol. 2004;24(11):2095-2101. (Pubitemid 39482436)
13. Ginnan R, Singer HA. PKC-delta-dependent pathways contribute to PDGF-stimulated ERK1/2 activation in vascular smooth muscle. Am J Physiol Cell Physiol. 2005;288(6):C1193-C1201. (Pubitemid 40991056)
14. Radhakrishnan Y, Maile LA, Ling Y, Graves LM, Clemmons DR. Insulin-like growth factor-I stimulates She-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells. J Biol Chem. 2008;283(24): 16320-16031.
15. Lewis JM, Cheresh DA, Schwartz MA. Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. J Cell Biol. 1996; 134(5): 1323-1332. (Pubitemid 26300175)
16. Capellini VK, Celotto AC, Baldo CF, et al. Diabetes and vascular disease: basic concepts of nitric oxide physiology, endothelial dysfunction, oxidative stress and therapeutic possibilities. Curr Vase Pharmacol. 2010;8(4):526-544.
17. Kappert K, Furundzija V, Fritzsche J, et al. Integrin cleavage regulates bidirectional signalling in vascular smooth muscle cells. Thromb Haemost. 2010;103(3):556-563.
18. Leduc I, Meloche S. Angiotensin II stimulates tyrosine phosphorylation of the focal adhesion-associated protein paxillin in aortic smooth muscle cells. J Biol Chem. 1995;270(9):4401-4404.
19. Li C, Wernig F, Leitges M, Hu Y, Xu Q. Mechanical stressactivated PKCdelta regulates smooth muscle cell migration. FASEB J. 2003;17(14):2106-2108.
20. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol. 1994;24(5):1398-1405. (Pubitemid 24331884)
21. Greif M, Pohl T, Oversohl N, Reithmann C, Steinbeck G, Becker A. Acute stent thrombosis in a sirolimus eluting stent after wasp sting causing acute myocardial infarction: a case report. Cases J. 2009;2:7800.
22. Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemost. 2010;8(3):454-462.
23. Gilio K, Harper MT, Cosemans JM, et al. Functional divergence of platelet PKC isoforms in thrombus formation on collagen. J Biol Chem.. 2010;285(30):23410-23419.
24. Konopatskaya O, Gilio K, Harper MT, et al. PKCalpha regulates platelet granule secretion and thrombus formation in mice. J Clin Invest. 2009;119(2):399-407.
25. Yoshioka A, Shirakawa R, Nishioka H, et al. Identification of protein kinase Calpha as an essential, but not sufficient, cytosolic factor for Ca2+-induced alphaand dense-core granule secretion in platelets. J Biol Chem. 2001;276(42):39379-39385.
26. Tabuchi A, Yoshioka A, Higashi T, et al. Direct demonstration of involvement of protein kinase Calpha in the Ca2+-induced platelet aggregation. J Biol Chem. 2003;278(29):26374-26379. (Pubitemid 36876776)
27. Pula G, Crosby D, Baker J, Poole AW. Functional interaction of protein kinase Calpha with the tyrosine kinases Syk and Src in human platelets. J Biol Chem. 2005;280(8):7194-7205. (Pubitemid 40341277)
28. Crosby D, Poole AW. Physical and functional interaction between protein kinase C delta and Fyn tyrosine kinase in human platelets. J Biol Chem. 2003;278(27):24533-24541. (Pubitemid 37548606)
29. Pula G, Schuh K, Nakayama K, Nakayama KI, Walter U, Poole AW. PKCdelta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation. Blood. 2006;108(13):4035-4044. (Pubitemid 44913272)
30. Hall KJ, Harper MT, Gilio K, Cosemans JM, Heemskerk JW, Poole AW. Genetic analysis of the role of protein kinase Ctheta in platelet function and thrombus formation. PLoS One. 2008; 3(9):e3277.
31. Chari R, Getz T, Nagy B Jr, et al. Protein kinase C[delta] differentially regulates platelet functional responses. Arterioscler Thromb Vase Biol. 2009;29(5):699-705.
32. Nagy B Jr, Bhavaraju K, Getz T, Bynagari YS, Kim S, Kunapuli SP. Impaired activation of platelets lacking protein kinase C-theta isoform. Blood. 2009;113(11):2557-2567.
33. Cohen S, Braiman A, Shubinsky G, Ohayon A, Altaian A, Isakov N. PKCtheta is required for hemostasis and positive regulation of thrombin-induced platelet aggregation and alpha-granule secretion. Biochem Biophys Res Commun. 2009;385(1):22-27.
34. Abdala-Valencia H, Cook-Mills JM. VCAM-1 signals activate endothelial cell protein kinase C-alpha via oxidation. J Immunol. 2006;177(9):6379-6387. (Pubitemid 44628856)
35. Kouroedov A, Eto M, Joch H, Volpe M, L̈scher TF, Cosentino F. Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 2004;110(1):91-96. (Pubitemid 38880139)
36. Javaid K, Rahman A, Anwar KN, Frey RS, Minshall RD, Malik AB. Tumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1. Circ Res. 2003;92(10): 1089-1097. (Pubitemid 36665854)
37. Ni CW, Wang DL, Lien SC, Cheng JJ, Chao YJ, Hsieh HJ. Activation of PKC-δ and ERK1/2 participates in shear-induced endothelial MCP-1 expression that is repressed by nitric oxide. J Cell Physiol. 2003;195(3):428-434. (Pubitemid 36529870)
38. Laudanna C, Mochly-Rosen D, Liron T, Constantin G, Butcher EC. Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis. J Biol Chem. 1998;273(46):30306- 30315. (Pubitemid 28545499)
39. Okazaki J, Mawatari K, Liu B, Kent KC. The effect of protein kinase C and its alpha subtype on human vascular smooth muscle cell proliferation, migration and fibronectin production. Surgery. 2000;128(2):192-197. (Pubitemid 30622483)
40. Campbell M, Trimble ER. Modification of PI3K- and MAPKdependent chemotaxis in aortic vascular smooth muscle cells by protein kinase Cbetall. Circ Res. 2005 ;96(2): 197-206. (Pubitemid 40209367)
41. Ohtsu H, Mifune M, Frank GD, et al. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vase Biol. 2005;25(9):1831-1836. (Pubitemid 41243450)
42. Kamiya K, Ryer E, Sakakibara K, Zohlman A, Kent KC, Liu B. Protein kinase C delta activated adhesion regulates vascular smooth muscle cell migration. J Surg Res. 2007;141(1):91-96. (Pubitemid 46898441)
43. Liu B, Ryer EJ, Kundi R, et al. Protein kinase C-delta regulates migration and proliferation of vascular smooth muscle cells through the extracellular signal-regulated kinase 1/2. J Vase Surg. 2007;45(1):160-168. (Pubitemid 46043543)
44. Ding Q, Chai H, Mahmood N, Zhou W. Resistin promotes vascular smooth muscle cell migration via matrix metalloproteinases. S. 2010;158(2):299.
45. Leszczynski D, Joenväärä S, Foegh ML. Protein kinase C-alpha regulates proliferation but not apoptosis in rat coronary vascular smooth muscle cells. Life Set 1996;58:599-606.
46. Marilley D, Mosieniak G, Boscoboinik D, Azzi A. Correlation between human vascular smooth muscle cell proliferation and protein kinase C alpha-expression: effect of d-alpha-tocopherol. Biochem Mol Biol Int. 1996;40(4):699-707. (Pubitemid 26396027)
47. Sasaguri T, Kosaka C, Hirata M, et al. Protein kinase C-mediated inhibition of vascular smooth muscle cell proliferation: the isoforms that may mediate Gl/S inhibition. Exp Cell Res. 1993; 208(1):311-20. (Pubitemid 23274518)
48. Wang S, Desai D, Wright G, Niles RM, Wright GL. Effects of protein kinase C alpha overexpression on A7r5 smooth muscle cell proliferation and differentiation. Exp Cell Res. 1997;236(1): 117-126. (Pubitemid 27452355)
49. Yamamoto M, Acevedo-Duncan M, Chalfant CE, Patel NA, Watson JE, Cooper DR. Acute glucose-induced downregulation of PKC-betall accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol. 2000;279(3):C587-C595.
50. Nakamura J, Kasuya Y, Hamada Y, et al. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia. 2001; 44(4):480-487. (Pubitemid 32324359)
51. Yasuda Y, Nakamura J, Hamada Y, et al. Role of PKC and TGFbeta receptor in glucose-induced proliferation of smooth muscle cells. Biochem Biophys Res Commun. 2001;281(1):71-77. (Pubitemid 32924401)
52. Heo KS, Kim DU, Kim L, et al. Activation of PKCbeta(II) and PKCtheta is essential for LDL-induced cell proliferation of human aortic smooth muscle cells via Gi-mediated Erkl/2 activation and Egr-1 upregulation. Biochem Biophys Res Commun. 2008;368(1):126-131.
53. Ling S, Little PJ, Williams MR, et al. High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells. Am J Physiol Endocrinol Metab. 2002; 282(4):E746-E751. (Pubitemid 34654736)
54. Andrassy M, Belov D, Harja E, et al. Central role of PKCbeta in neointimal expansion triggered by acute arterial injury. Circ Res. 2005;96(4):476-483. (Pubitemid 40354542)
55. Skaletz-Rorowski A, Eschert H, Leng J, et al. PKC delta-induced activation of MAPK pathway is required for bFGF-stimulated proliferation of coronary smooth muscle cells. Cardiovasc Res. 2005;67(1):142-150. (Pubitemid 40798301)
56. Leitges M, Mayr M, Braun U, et al. Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J Clin Invest. 2001; 108(10):1505-1512. (Pubitemid 33091988)
57. Zhao Y, Liu J, Li L, Liu L, Wu L. Role of Ras/PKCzeta/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul Pept. 2005;128(1): 43-50. (Pubitemid 40255533)
58. Parmentier JH, Zhang C, Estes A, Schaefer S, Malik KU. Essential role of PKC-zeta in normal and angiotensin II-accelerated neointimal growth after vascular injury. Am J Physiol Heart Circ Physiol. 2006;291(4):H1602-H1613. (Pubitemid 44497664)
59. Hussain S, Assender JW, Bond M, Wong LF, Murphy D, Newby AC. Activation of protein kinase Czeta is essential for cytokine-induced metalloproteinase-1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation. J Biol Chem. 2002;277(30):27345-27352. (Pubitemid 34951754)
60. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part I. Circulation. 2002;106(21):2734-2740. (Pubitemid 35364930)
61. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small moleculekinase interaction map for clinical kinase inhibitors. Nat Biotech nol. 2005;23(3):329-336. (Pubitemid 41094421)
62. Yang CM, Chien CS, Hsiao LD, et al. Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol. 2001; 132(7): 1531-1541.
63. Mamputu JC, Levesque L, Renier G. Proliferative effect of lipoprotein lipase on human vascular smooth muscle cells. Arterioscler Thromb Vase Biol. 2000;20(10):2212-2219.
64. Pang X, Sun NL. Calcineurin-NFAT signaling is involved in phenylephrine-induced vascular smooth muscle cell proliferation. Acta Pharmacol Sin. 2009;30(5):537-544.
65. Ferro T, Neumann P, Gertzberg N, Clements R, Johnson A. Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol. 2000;278(6):L1107-L1117. (Pubitemid 30439233)
66. Stebbins EG, Mochly-Rosen D. "Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C." J Biol Chem. 2001 ;276(32):29644-29650.
67. Cho HM, Choi SH, Hwang KC, et al. The Src/PLC/PKC/MEK/ERK signaling pathway is involved in aortic smooth muscle cell proliferation induced by glycated LDL. Mol Cells. 2005;19(1): 60-66.
68. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens. 2001 ;19(12):2191-2196. (Pubitemid 33135241)
69. Watanabe T, Pakala R, Katagiri T, Benedict CR. Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. J Vase Res. 2001;38(4):341-349. (Pubitemid 32678949)
70. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 2001; 104(1):16-18. (Pubitemid 32623283)
71. Yano K, Bauchat JR, Liimatta MB, Clemmons DR, Duan C. Down-regulation of protein kinase C inhibits insulin-like growth factor I-induced vascular smooth muscle cell proliferation, migration, and gene expression. Endocrinology. 1999;140(10): 4622-4632. (Pubitemid 30666129)
72. Cogo A, Napolitano G, Michoud MC, Barbon DR, Ward M, Martin JG. Effects of hypoxia on rat airway smooth muscle cell proliferation. J Appl Physiol. 2003;94(4): 1403-1409. (Pubitemid 36348816)
73. Chen L, Hahn H, Wu G, et al. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and δ PKC. Proc Natl Acad Sci USA. 2001 ;98(20): 11114-11119. (Pubitemid 32928691)
74. Bates E, Bode C, Costa M, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation. 2008; 117(7):886-896. (Pubitemid 351272586)
75. Soltoff SP. Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci. 2007;28(9):453-458. (Pubitemid 47371266)
76. Harrison DG, Sayegh H, Ohara Y, et al. Regulation of expression of the endothelial cell nitric oxide synthase. Clin Exp Pharmacol Physiol. 1996;23:251-255. (Pubitemid 26167432)
77. Rosales OR, Isales CM, Bhargava J. Overexpression of protein kinase C alpha and betal has distinct effects on bovine aortic endothelial cell growth. Cell Signal. 1998;10(8):589-597. (Pubitemid 28438336)
78. Xu H, Goettsch C, Xia N, et al. Differential roles of PKCalpha and PKCδ in controlling the gene expression of Nox4 in human endothelial cells. Free Radic Biol Med. 2008;44(8):1656-1667.
79. Tanaka M, Terry RD, Mokhtari GK, et al. Suppression of graft coronary artery disease by a brief treatment with a selective δPKC activator and a deltaPKC inhibitor in murine cardiac allografts. Circulation. 2004;110(11 suppl 1):II194-II199. (Pubitemid 39263722)
80. Tanaka M, Gunawan F, Terry RD, et al. Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators. J Thorac Cardiovasc Surg. 2005;129(5):1160-1167. (Pubitemid 40631440)
81. Whitson EL, Bugni TS, Chockalingam PS, et al. Spheciosterol sulfates, PKCzeta inhibitors from a Philippine sponge Spheciospongia sp. J Nat Prod. 2008;71(7):1213-1217.
82. Kastrati A, Schuhlen H, Hausleiter J, et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation. 1997;96(2):462-467. (Pubitemid 27329421)
83. Ellis SG, Effron MB, Gold HK, et al. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999;100(8):799-806. (Pubitemid 29398876)
84. Lee CW, Chae JK, Lim HY, et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J. 1999;138(1 pt 1):60-63.
85. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vase Biol. 2002;22(11): 1769-1776. (Pubitemid 35315761)
86. Rodriguez AE, Fernandez-Pereira C. Systemic immunosuppressive therapy with oral Sirolimus after bare metal stent implantation: the missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions. Recent Pat Cardiovasc Drug Discov. 2008;3(3):201-208.
87. Kuchulakanti P, Waksman R. Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis. Drugs. 2004;64(21):2379-2388. (Pubitemid 39472627)
88. Inagaki K, Koyanagi T, Berry NC, Sun L, Mochly-Rosen D. Pharmacological inhibition of δ-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension. 2008;51(6):1565-1569.
89. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part i. Circulation. 2002;106(21):2734-2740. (Pubitemid 35364930)
90. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation. 2002;106(22):2859-2866. (Pubitemid 35396988)